Development and utility of pirfenidone in the treatment of idiopathic pulmonary fibrosis: Review of preclinical science and recent clinical trials

Transplant Research and Risk Management

Volumn 3, Issue , 2011, Pages 55-63

  Jackson, Robert M ^a   Gomez Marin, Orlando ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Idiopathic pulmonary fibrosis; Pirfenidone; Redox signaling

Indexed keywords

ACETYLCYSTEINE; AZATHIOPRINE; BOSENTAN; CORTICOSTEROID; MITOGEN ACTIVATED PROTEIN KINASE; PIRFENIDONE; PLACEBO; PREDNISONE; REACTIVE OXYGEN METABOLITE;

CELL PROLIFERATION; COLLAGEN SYNTHESIS; DIARRHEA; DIZZINESS; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG ERUPTION; DRUG MEGADOSE; DRUG TISSUE LEVEL; DRUG TREATMENT FAILURE; DYSPEPSIA; FATIGUE; FIBROBLAST; FIBROSING ALVEOLITIS; GASTROINTESTINAL SYMPTOM; HUMAN; INFLAMMATION; LOW DRUG DOSE; LUNG FUNCTION; LUNG TRANSPLANTATION; NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY DISORDER; PROGRESSION FREE SURVIVAL; REVIEW;

EID: 80052615769     PISSN: None     EISSN: 11791616     Source Type: Journal    
DOI: 10.2147/TRRM.S16205     Document Type: Review

References (60)

1. Azuma A. Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis. Expert Rev Resp Med. 2010;4(3):301-310.
2. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Resp J. 2010;35:821-829.
3. Iyer S, Wild J, Schiedt M, et al. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J Labs Clin Med. 1995;125: 779-785.
4. Iyer S, Gurujeyalashmi G, Giri S. Effects of pirfenidone on transforming growth factor-β gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Therap. 1999;291: 367-373.
5. Shi S, Wu J, Chen H, Chen H, Wu J, Zeng F. Single-and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent in healthy Chinese volunteers. J Clin Pharmacol. 2007;47:1268-1276.
6. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus. Classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2002;165:277-304.
7. Korfei M, Ruppert C, Mahavai P, et al. Epithelial endoplasmic reticulum stress and apoptosis in sporadic idiopathic pulmonary fibrosis. Am J Repir Crit Care Med. 2008;178:838-846.
8. Raghu G, Weycker D, Edelberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174:810-816.
9. Thomas AQ, Lane K, Phillips III J, et al. Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am J Respir Crit Care Med. 2002;165:1322-1328.
10. Baumgartner KB, Samet JM, Stidley CA, Colby TV, Waldron JA; For Division of Epidemiology and Cancer Control, University of New Mexico Health Sciences Center. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1997;155: 242-248.
11. Taskar VS, Coultas DB. Is idiopathic pulmonary fibrosis and environmental disease? Proc Am Thorac Soc. 2006;3:293-298.
12. Raghu G, Freudenberger TD, yang S, et al. High prevalence of abnormal acid gastro-esophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J. 2006;27:136-142.
13. Wells AU, Hirani N. Interstitial lung disease guideline. Thorax. 2008; 63:v1-v58.
14. Thannickal VJ, Toews GB, White ES, Lynch III J P, Martinez FJ. Mechanisms of pulmonary fibrosis. Annu Rev Med. 2004;55:395-417.
15. Lynch DA, Godwin D, Safrin S, et al. High-resolution computed tomography in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;172:488-493.
16. Rudd R, Harlem PL, Turner-Warwick M. Cryptogenic fibro singal-veolitis. Relationships of pulmonary physiology and bronchoalveolar lavage to response to treatment and prognosis. Am Rev Respir Dis. 1981;124:1-8.
17. Douglas W W, Ryu JH, Schroeder DR. Idiopathic pulmonary fibrosis: impact of oxygen and colchicine, prednisone, or no therapy on survival. Am J Respir Crit Care Med. 2000;161:1172-1178.
18. Turner-Warwick M, Burrows B, Johnson A. Cryptogenic fibrosingal-veolitis: response to corticosteroid treatment and its effect on survival. Thorax. 1980;35:593-599.
19. Gulsvik A, Kjelsberg F, Bergmann A, Froland SS, Rootwelt K, Vale JR. High-dose intravenous methylprednisolone pulse therapy as initial treatment in cryptogenic fbrosingalveolitis. A pilot study. Respiration. 1986;50:252-257.
20. Nagai S, Kadaicha M, Ramada K, et al. Hospital-based historical cohort study of 234 histologically proven Japanese patients with IPF. Sarc Vasc Diff Lung Dis. 1999;16:209-214.
21. Selman M, Carrillo G, Salas J, et al. Colchicine, D-penicillamine, and prednisone in the treatment of idiopathic pulmonary fibrosis: a controlled clinical trial. Chest. 1998;114:507-512.
22. Johnson MA, Kwan S, Snell NJ, Nunn Al, Darbyshire JH, Turner-Warwick M. Randomized controlled trial comparing predniso-lone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibro singalveolitis. Thorax. 1989;44:280-288.
23. Raghu G, Depose EG, Cain K, et al. Azathioprine combined with pred-nisone in the treatment of idiopathic pulmonary fibrosis: a prospective double blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis. 1991;144:291-296.
24. Winterbauer RH, Hammar S P, Hallman KO, et al. Diffuse interstitial pneumonitis. Clinicopathologic correlations in 20 patients treated with prednisone/azathioprine. Am J Med. 1978;65:661-672.
25. Behera D, Gupta D, Lindal SK. Response to steroid therapy in patients of idiopathic pulmonary fibrosis: a retrospective analysis. Indian J Chest Dis Allied Sci. 1998;40:163-169.
26. O'Donnell K, Keogh B, Cantin A, Crystal RG. Pharmacologic suppression of the neutrophil component of the alveolitis in idiopathic pulmonary fibrosis. Am Rev Respir Dis. 1987;136:288-292.
27. King TE, Behr J, Brown KK, et al. Build-1: randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;177:75-81.
28. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005;353:2229-2224.
29. Richeldi L, Davies H, Ferrara G, Franco F. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev. 2003;(3):CD002880.
30. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171:1040-1047.
31. Macias-Barragan J, Sandoval-Rodriguez A, Navarro-Partida J, Armendariz-Borunda J. The multifaceted role of pirfenidone and its novel targets. Fibrogenesis Tissue Repair. 2010;3:16.
32. Misra H, Rabideau C. Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals. Molec Cell Biochem. 2000;204:119-126.
33. Mitani Y, Sato K, Muramoto Y, et al. Superoxide scavenging activity of pirfenidone-iron complex. Biochem Biophys Res Commun. 2008;372: 19-23.
34. Saleh D, Barnes PJ, Giaid A. Increased production of the potent oxidant peroxynitrite in the lungs of patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1997;155:1763-1769.
35. Giri S, Wang Q, Xie Y, et al. Pharmacokinetics and metabolism of a novel antifbrotic drug pirfenidone, in mice following intravenous administration. Biopharm Drug Dispos. 2002;23:203-211.
36. Bruss M, Margolin S, Giri S. Pharmacokinetics of orally administered pirfenidone in male and female beagles. J Vet Pharmacol Therap. 2004;27:361-367.
37. Bruss M, Stanley S, Margolin S, Giri S. Pharmacokinetics and metabolism of intravenous pirfenidone in sheep. Biopharm Drug Dispos. 2008; 29:119-126.
38. Rubino C, Bhavnani S, Ambrose P, Forrest A, Loutit J. Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther. 2009;22:279-285.
39. Taniyama M, Ohbayashi S, Narita M, et al. Pharmacokinetics of an anti-fbrotic agent, pirfenidone, in hemodialysis patients. Eur J Pharmacol. 1997;52:77-78.
40. Iyer S, Margolin S, Hyde D, Giri S. Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model. Exp Lung Res. 1998;24:119-132.
41. Kehrer J, Margolin J. Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice. Toxicol Letters. 1997;90:125-132.
42. Nakazato H, Oku H, yamane S, Tsuruta Y, Suzuki R. A novel anti-fbrotic agent pirfenidone suppresses tumor necrosis factor-α at the translational level. Eur J Pharmacol. 2002;446:177-185.
43. Iyer S, Gurujeyalakshmi G, Giri S. Effects of pirfenidone on procol-lagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharm Exp Therap. 1999;289:211-218.
44. Gurujeyalakshmi G, Hollinger M, Giri S. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am J Physiol. 1999;276:L311-L318.
45. Spond J, Case N, Crawley C, et al. Inhibition of experimental acute pulmonary infammation by pirfenidone. Pulmon Pharmacol Therapeutics. 2003;16:207-214.
46. Liu H, Drew P, Cheng Y, Visner G. Pirfenidone inhibits infammatory responses and ameliorates allograft injury in a rat lung transplant model. Cardiothoracic Transplant. 2005;130:852-858.
47. Liu H, Drew P, Gaugler A, Cheng Y, Visner G. Pirfenidone inhibits lung allograft fibrosis through L-arginine-arginase pathway. Am J Transplant. 2005;5:1256-1263.
48. Dosanjh A. Pirfenidone: a novel potential therapeutic agent in the management of chronic allograft rejection. Transplant Proc. 2007;39: 2153-2156.
49. Kuo E, Bharat A, Dharmarajan S, Fernandez F, Patterson G, Mohanakuma T. Animal models for bronchiolitis obliterans syndrome following human lung transplantation. Immunologic Res. 2005;33: 69-81.
50. Raghu G, Johnson C, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifbrotic agent, pirfenidone. Am J Resp Crit Care Med. 1999;159:1061-1069.
51. Noble P, Albera C, Bradford W, et al. Effect of pirfenidone on lung function and progression-free survival (PFS) in patients with idiopathic pulmonary fibrosis (IPF): a meta-analysis of three phase 3 studies. Am J Resp Crit Care Med. 2010;181:A1257.
52. Collard H. Idiopathic pulmonary fibrosis and pirfenidone. Eur Respir J. 2010;35:728-729.
53. Swigris J. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;36(3):695-696.
54. Spagnolo P, Del Giovane C, Luppi F, et al. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev. 2010;8(9): CD003134.
55. Park H, Bao L, Kim Y, et al. Pirfenidone suppressed the development of glomerulosclerosis in the FGS/Kist mouse. J Korean Med Sci. 2003; 18:527-533.
56. Giri S, Al-Bayati M, Du X, Schelegle E, Mohr F, Margolin S. Amelioration of doxorubicin induced cardiac and renal toxicity by pir-fenidone in rats. Cancer Chemother Pharmacol. 2004;53:141-150.
57. Leh S, Vaagnes O, Margolin S, Iverson B, Forslund T. Pirfenidone and candesartan ameliorate morphological damage in mild chronic anti-GBM nephritis in rats. Nephrol Dial Transplant. 2005;20:71-82.
58. Cho M, Smith D, Branton M, Penzak S, Kopp J. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2007;2:906-913.
59. Garcia L, Hernandez I, Sandoval A, et al. Pirfenidone effectively reverses experimental liver fibrosis. J Hepatol. 2002;37:797-805.
60. Amenariz-Borunda J, Islas M, Meza Garcia E, et al. A pilot study in patients with established advanced liver fibrosis using pirfenidone. Gut. 2006;55:1663-1665.